Modality - Right to Try / international
Ibogaine treatment providers
Ibogaine is a long-acting iboga alkaloid being studied for opioid use disorder, PTSD and treatment-resistant depression. It remains DEA Schedule I at the federal level, but the 2025 White House Initiative on Psychedelic Medicine directed the FDA and VA to fast-track ibogaine trials for veterans under the federal Right to Try Act. Outside of enrolled US trials, most Americans access ibogaine through licensed centers in Mexico, Canada or the Netherlands.
- Federal status
- DEA Schedule I (US)
- Right to Try
- Open to eligible veterans (2025+)
- VA trial sites
- NY / CA / OR (active recruiting)
- Session length
- 24-36 hour supervised dose
0 verified providers
Common questions
Is ibogaine legal in the United States?
Not for general recreational or clinical use - it is DEA Schedule I. But the federal Right to Try Act (2018) allows patients with life-threatening conditions to access eligible investigational drugs outside of clinical trials. The April 2025 White House directive explicitly names ibogaine as a candidate for that pathway, and the VA is enrolling veterans in FDA-sanctioned trials.
Can veterans access ibogaine through the VA?
Yes, on a limited basis. The VA is running FDA-sanctioned ibogaine PTSD trials at several sites, coordinated with Stanford's PTSD research team and private non-profits. If you do not qualify for a trial, the 2025 executive order opens a Right to Try path that can be coordinated through a VA or private psychiatrist.
What about clinics in Mexico?
Several Mexico- and Canada-based clinics operate legally under their own national frameworks and treat US patients. Before booking, confirm medical screening (EKG, liver panel, QT interval), 24-hour cardiac monitoring, and a licensed MD on site. Ibogaine has real cardiac risk - unsupervised dosing has been associated with fatal arrhythmias.